pca commentary: metastatic hormone sensitive prostate cancer (mhspc): many treatment options
Published 1 year ago • 678 plays • Length 13:09Download video MP4
Download video MP3
Similar videos
-
16:26
patient selection in metastatic hormone-sensitive prostate cancer (mhspc)
-
17:44
new approaches to metastatic hormone sensitive prostate cancer
-
8:11
pca commentary november 2021
-
7:59
pca commentary september 2021
-
5:33
pca commentary for october 2021: therapy of the primary tumor in newly diagnosed mhspc
-
10:07
pca commentary: sequencing bipolar androgen therapy (bat) with xtandi- an effective option
-
3:51
metastatic hormone-sensitive prostate cancer (mhspc)
-
1:01:45
metastatic hormone sensitive prostate cancer: expert guidance for urologists
-
1:18:13
urowebinar: paradigm shifts in metastatic hormone sensitive prostate cancer mhspc recent treatment
-
12:42
pca commentary - nmcrpc and androgen receptor inhibition: enzalutamide, apalutamide and darolutamide
-
3:13
pca commentary june 2021 - treatment-induced neuroendocrine prostate cancer
-
19:50
new standards of care for advanced prostate cancer
-
1:06:24
metastatic hormone sensitive prostate cancer
-
2:35
pca commentary may 2021 - psma targeted radioiigand therapy for metastatic prostate cancer
-
5:11
enzalutamide adt in men with de novo mhspc: the arches trial
-
1:07
dr. penson on treatment selection in metastatic hormone-sensitive prostate cancer
-
6:02
update on the arches trial: new indication for enzalutamide in mhspc
-
48:10
urowebinar: paradigm shifts in metastatic hormone sensitive prostate cancer: recnt treatmnt dvlpmnts
-
1:17
treatment landscape for metastatic hormone-sensitive prostate cancer